Latest Conference Articles

Oncology nurses present their experiences treating patients with sotorasib in the phase 1/2 CodeBreaK 100 trial and optimal symptom management strategies to improve patient outcomes with the drug.

Sacituzumab govitecan-hziy significantly improved progression-free survival in patients with HER2-low expressing TNBC and HER2-negative disease.

An hourly rounding column helped make integrated data points more visible and improve nurse responsiveness on an inpatient floor.

Darolutamide significantly prolonged metastasis-free survival compared with placebo in men with nonmetastatic castration-resistant prostate cancer with no added toxicity.

Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, discusses how collaboration between an oncology unit and discharge lounge can improve discharge times for patients who have undergone stem cell transplantation.

A medication extension set may be the preferred method for subcutaneous hyaluronidase injections compared with a traditional needle.

Michelle Mollica, PhD, MPH, RN, OCN, senior advisor in the NCI Office of Cancer Survivorship, discusses different long-term care considerations for nurses caring for patients with cancer.

The combination of PARP inhibition and androgen receptor targeted therapy was found to be tolerable in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations.

Brianna Lutz, MSN, RN, OCN, discusses a red-and-green dot hourly column that shows which patients with cancer have been attended to in the past hour.

Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, demonstrated a manageable toxicity profile for patients with advanced prostate cancer.

Patricia Jakel, RN, MN, AOCN, discusses burnout and compassion fatigue in acute oncology care.

In patients receiving immune checkpoint inhibition to treat their metastatic urothelial carcinoma, immune-related adverse effects may serve as a prognostic marker for progression-free and overall survival.

A post-hoc analysis of the phase 3 ARCHES found enzalutamide plus androgen deprivation therapy to be an effective treatment for patients with metastatic hormone-sensitive prostate cancer, no matter their history of prior local therapy.

Patients with locally advanced muscle invasive bladder cancer may experience superior benefit from gemcitabine and carboplatin if the chemotherapy is co-administered with vitamin c.

Entrectinib elicited encouraging responses in patients with breast cancer that harbors NTRK fusions, according to updates from the phase 2 STARTRK-2 trial.

Patients with clear cell renal cell carcinoma experienced reduced levels of hypoxia inducible factor-2 alpha expression following treatment with ARO-HIF2.

Kate Sandstrom, MSN, APRN-BC, AOCN, discusses the importance of including the radiation oncology team in a patient’s long-term care plan.

Oncology nurses at the 2022 ASTCT Meeting shared how a peer-to-peer observation and validation tool helped decrease central line-associated bloodstream infections by 68%.

Unrelieved stress may contribute to cancer-related cognitive impairment and anxiety in patients undergoing chemotherapy.

In the age of cyberattacks, establishing and practicing a downtime procedure is crucial to safeguard patient care, according to Kelli-Ann Mancini, MSN, RN, OCN.

Older men who have received androgen-deprivation therapy are an increased risk of heart issues, however, the root of the risk is still not well understood.

Cognitive therapies were found to be effective for helping cancer survivors with insomnia, but more research is needed for patients actively receiving treatment.

Oncology nurses may be able decrease peripheral access wait times for patients, however, a change in culture may be necessary to see full results.

Jessica MacIntyre, ARNP, NP-C, AOCNP, discusses empowering oncology nurse navigators to refer patients undergoing chemotherapy or radiation therapy to nutrition services.

Single nucleotide polymorphism (SNP) genotyping could be used to predict radiation dermatitis in patients with breast cancer.

Increasing the number of intravenous port nurse champions across a health care system helps to keep oncology nurses with their patients and reduce care delays.

The death doula is a unique role that can help oncology care teams improve the quality of end-of-life care delivered to patients.

The addition of apalutamide to androgen deprivation therapy does not lead to a significant patient-reported side effect burden nor a reduction in health-related quality of life in patients with metastatic castration-sensitive prostate cancer.

Patients with cancer were reported to have mixed expectations with immunotherapy as part of their oncology treatment.

The addition of ublituximab and umbralisib (Ukoniq; U2) to ibrutinib (Imbruvica) demonstrated a 77% undetectable minimal residual disease (uMRD) rate in patients with chronic lymphocytic leukemia.